@tickeron $ICPT this was beaten to death last year the price its at post run post reversal is oversold territory; where it sits now Longer term perspective its in oversold territory still. <30 is not oversold that's less than cash and less than PBC value so there is no chance it reverses post reversal and hits that level that's lower then cash and lower then a pipeline asset that has no material issues. The analysis lacks any factoring of DD. Filed NDA in NASH which FDA maks a descion on this month. Meanwhile Nov 8th-12th the company will be presenting 22 abstracts at AASLD.